Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;36(3):548-562.
doi: 10.1007/s12325-019-0880-8. Epub 2019 Feb 4.

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review

Karissa M Johnston  1 , David R Walker  2 , Pardis Lakzadeh  3
Affiliations

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review

Karissa M Johnston et al. Adv Ther. 2019 Mar.

Abstract

Introduction: The objective was to identify the most commonly used patient-reported outcome (PRO) instruments for overactive bladder (OAB), determine which are the most useful for measuring burden in OAB and characterize the findings of recent studies that have employed PRO instruments to assess OAB symptoms and the effects of treatment.

Methods: A systematic search of OAB literature published between January 2006 and November 2017 using Medline/PubMed and EMBASE databases.

Results: Of 3425 abstracts and 500 full-text articles reviewed, 58 studies (both clinical trials and observational studies) were included in the review. The most commonly used PRO instruments were the OAB Questionnaire (OAB-q; 64%), followed by the King's Health Questionnaire (KHQ; 31%) and the Patient Perception of Bladder Condition (PCBC; 21%). Synthesis of data from studies using the OAB-q showed that OAB treatment with antimuscarinics, mirabegron and onabotulinumtoxinA all improve health-related quality of life (HRQoL) and symptoms beyond the benefits observed with placebo. The OAB-q could detect dose-response relationships in some studies and demonstrated there were no significant differences across therapies from different drug classes.

Conclusion: The HRQoL burden of OAB and response to treatment can be reliably measured by PRO instruments, and the OAB-q is the most commonly used instrument in OAB, particularly in clinical trials of OAB interventions. These data will be useful to provide benchmarks of burden levels for PRO scores obtained among those on contemporary therapies for comparison with outcomes from patients managed with emerging treatments.

Funding: Astellas Pharma Global Development, Inc.

Keywords: Overactive bladder; Patient reported outcome; Quality of life; Urinary incontinence; Urology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of records identified, included and excluded
Fig. 2
Fig. 2
Baseline OAB-Q scores in included studies. All individual treatment arms within studies are included as a separate row. The overall HRQOL and symptom bother scale are included as separate columns. The four subscales (coping, concern, sleep, social) of the overall HRQOL are also included as separate columns. The Range of OAB-Q score is 0-100 (where a higher symptom bother score indicates greater symptom bother, while lower HRQOL scores indicate greater impact on QOL)
Fig. 3
Fig. 3
OAB-Q change scores in included studies. All individual treatment arms within studies are included as a separate row. The overall HRQoL and symptom bother scale are included as separate columns. The four subscales (coping, concern, sleep, social) of the overall HRQoL are also included as separate columns. Range of minimum important difference (MID) = 10.0 for all scales
See this image and copyright information in PMC

References

    1. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007;17(4):231–236. - PubMed
    1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087. - PubMed
    1. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95. - PubMed
    1. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. - PubMed
    1. Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029–1039. - PubMed

Publication types

MeSH terms